Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) EPS (Basic): 2009-2024

Historic EPS (Basic) for Gyre Therapeutics (GYRE) over the last 16 years, with Dec 2024 value amounting to $0.14.

  • Gyre Therapeutics' EPS (Basic) rose 300.00% to $0.04 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.07, marking a year-over-year increase of 105.26%. This contributed to the annual value of $0.14 for FY2024, which is 109.93% up from last year.
  • According to the latest figures from FY2024, Gyre Therapeutics' EPS (Basic) is $0.14, which was up 109.93% from -$1.41 recorded in FY2023.
  • In the past 5 years, Gyre Therapeutics' EPS (Basic) ranged from a high of $0.14 in FY2024 and a low of -$2.93 during FY2020.
  • Moreover, its 3-year median value for EPS (Basic) was -$0.26 (2022), whereas its average is -$0.51.
  • In the last 5 years, Gyre Therapeutics' EPS (Basic) tumbled by 442.31% in 2023 and then skyrocketed by 109.93% in 2024.
  • Gyre Therapeutics' EPS (Basic) (Yearly) stood at -$2.93 in 2020, then increased by 2.05% to -$2.87 in 2021, then surged by 90.94% to -$0.26 in 2022, then tumbled by 442.31% to -$1.41 in 2023, then skyrocketed by 109.93% to $0.14 in 2024.